Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,339 result(s) found. Displaying page 795 of 2,217.
    «« First « Previous 791  792  793  794  795  796  797  798  799  Next» Last»»
    EudraCT Number: 2014-000627-24 Sponsor Protocol Number: 000134 Start Date*: 2014-06-26
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and s...
    Medical condition: Idiopathic growth hormone deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004604-19 Sponsor Protocol Number: CAR-ERA Start Date*: 2014-08-06
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rh...
    Medical condition: patients with early progressive rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10066578 Progression of rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001714-26 Sponsor Protocol Number: CYD29 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003397-27 Sponsor Protocol Number: BDB-AS-301 Start Date*: 2014-04-02
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered...
    Medical condition: Persistent Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002287-24 Sponsor Protocol Number: 201105-RCTTEG Start Date*: 2012-07-11
    Sponsor Name:Erasmus MC
    Full Title: Massive blood loss in children during multiple trauma or major surgery: Fibrinogen therapy for massive blood loss during elective surgery for craniosynostosis repair, a double blinded randomized c...
    Medical condition: massive blood loss in surgery for premature fusion of cranial sutures, massive blood loss in fused bones of the skull
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10005645 Blood loss of (NOS) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004825-26 Sponsor Protocol Number: G200712 Start Date*: 2013-01-25
    Sponsor Name:GTx, Inc.
    Full Title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on and...
    Medical condition: Assessments of serum total testosterone, serum free testosterone, serum SHGB and serum PSA concentrations will be made. Bone turnover markers and the incidence and frequency of hot flashes will be ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004824-39 Sponsor Protocol Number: 1 Start Date*: 2015-09-18
    Sponsor Name:UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
    Full Title: The use of GnRH antagonist versus co-flare protocol for women with low ovarian reserve undergoing first cycle of in vitro fertilization
    Medical condition: response to ovarian stimulation in women with reduced ovarian reserve undergoing first cycle of in vitro fertilisaion.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10056204 In vitro fertilisation PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004458-33 Sponsor Protocol Number: CMX001-205 Start Date*: 2014-11-27
    Sponsor Name:Chimerix UK Limited
    Full Title: An Open-Label, Multicenter Study of the Safety, Tolerability and Antiviral Activity of Brincidofovir (CMX001) for Treatment of Ebola Virus Disease
    Medical condition: Ebola Virus Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001198-15 Sponsor Protocol Number: R668-AD-1334 Start Date*: 2015-01-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-000515-14 Sponsor Protocol Number: GESIDA8014 Start Date*: 2014-06-26
    Sponsor Name:Fundación SEIMC-GESIDA
    Full Title: Comparative, randomized, open study to evaluate maintenance with Darunavir/ritonavir once daily plus Lamivudine once daily versus continuing Darunavir/ritonavir once-daily plus Tenofovir/Emtricitab...
    Medical condition: HIV chronic infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005505-51 Sponsor Protocol Number: DPIDM-2012-01 Start Date*: 2013-05-01
    Sponsor Name:University College Dublin
    Full Title: Dipeptidyl peptidase-4 Inhibition in Psoriasis patients with diabetes (DIP): A Randomized Clinical Trial.
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003354-24 Sponsor Protocol Number: 2013-NIGRAM-VUMC-001 Start Date*: 2015-01-08
    Sponsor Name:Vrij Universiteit Medical Center
    Full Title: Influence of exogenous growth hormone administration on circulating levels of Klotho in healthy and CKD subjects
    Medical condition: Cardiovascular disease in chronic kidney disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003697-26 Sponsor Protocol Number: MK8835-006 Start Date*: 2014-07-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of ...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin and sitagliptin.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) FI (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001358-81 Sponsor Protocol Number: CTPX01 Start Date*: 2014-05-20
    Sponsor Name:Coretherapix S.L.U.
    Full Title: "First-in-human clinical trial, double blind, randomized with placebo, open for the six first patients (dose ranging), to evaluate the safety and efficacy of intracoronary infusion of allogeneic hu...
    Medical condition: Acute Myocardial Infarction (AMI): "First STEMI submitted to elective primary PCI with successful revascularization by PCI (TIMI = 3), but intermediate-high risk of HF development (infarct size by...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001417-32 Sponsor Protocol Number: CNTO136ARA3005 Start Date*: 2014-06-02
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-002072-92 Sponsor Protocol Number: B5161002 Start Date*: 2014-12-30
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 In Ambulatory Boys With ...
    Medical condition: Duchenne's Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001457-16 Sponsor Protocol Number: D4711C00001 Start Date*: 2015-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhale...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003561-34 Sponsor Protocol Number: PCYC-1121-CA Start Date*: 2014-01-07
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma
    Medical condition: Relapsed or refractory marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016853-16 Sponsor Protocol Number: MGN1601-CT1 Start Date*: 2010-08-31
    Sponsor Name:MOLOGEN AG
    Full Title: A Phase I/II, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic ...
    Medical condition: Advanced renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038394 Renal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002481-12 Sponsor Protocol Number: MT-3995-E07 Start Date*: 2012-09-07
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with nephropathy and Albuminuria'
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 791  792  793  794  795  796  797  798  799  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 11:39:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA